These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

565 related items for PubMed ID: 19329758

  • 1. Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21.
    Derks S, Bosch LJ, Niessen HE, Moerkerk PT, van den Bosch SM, Carvalho B, Mongera S, Voncken JW, Meijer GA, de Bruïne AP, Herman JG, van Engeland M.
    Carcinogenesis; 2009 Jun; 30(6):1041-8. PubMed ID: 19329758
    [Abstract] [Full Text] [Related]

  • 2. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
    Tada Y, Brena RM, Hackanson B, Morrison C, Otterson GA, Plass C.
    J Natl Cancer Inst; 2006 Mar 15; 98(6):396-406. PubMed ID: 16537832
    [Abstract] [Full Text] [Related]

  • 3. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.
    Magdinier F, Wolffe AP.
    Proc Natl Acad Sci U S A; 2001 Apr 24; 98(9):4990-5. PubMed ID: 11309512
    [Abstract] [Full Text] [Related]

  • 4. Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma.
    Carvalho AL, Chuang A, Jiang WW, Lee J, Begum S, Poeta L, Zhao M, Jerónimo C, Henrique R, Nayak CS, Park HL, Brait MR, Liu C, Zhou S, Koch W, Fazio VM, Ratovitski E, Trink B, Westra W, Sidransky D, Moon CS, Califano JA.
    Cancer Res; 2006 Oct 01; 66(19):9401-7. PubMed ID: 17018594
    [Abstract] [Full Text] [Related]

  • 5. The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island.
    Zhao W, Soejima H, Higashimoto K, Nakagawachi T, Urano T, Kudo S, Matsukura S, Matsuo S, Joh K, Mukai T.
    J Biochem; 2005 Mar 01; 137(3):431-40. PubMed ID: 15809347
    [Abstract] [Full Text] [Related]

  • 6. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC, Yu Y.
    Cancer Res; 2003 Jul 15; 63(14):4174-80. PubMed ID: 12874023
    [Abstract] [Full Text] [Related]

  • 7. The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma.
    Qiu GH, Tan LK, Loh KS, Lim CY, Srivastava G, Tsai ST, Tsao SW, Tao Q.
    Oncogene; 2004 Jun 10; 23(27):4793-806. PubMed ID: 15122337
    [Abstract] [Full Text] [Related]

  • 8. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer.
    Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, Tokino T.
    Cancer Res; 2008 Jun 01; 68(11):4123-32. PubMed ID: 18519671
    [Abstract] [Full Text] [Related]

  • 9. Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells.
    Kim TY, Jong HS, Song SH, Dimtchev A, Jeong SJ, Lee JW, Kim TY, Kim NK, Jung M, Bang YJ.
    Oncogene; 2003 Jun 19; 22(25):3943-51. PubMed ID: 12813468
    [Abstract] [Full Text] [Related]

  • 10. Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer.
    Obata T, Toyota M, Satoh A, Sasaki Y, Ogi K, Akino K, Suzuki H, Murai M, Kikuchi T, Mita H, Itoh F, Issa JP, Tokino T, Imai K.
    Clin Cancer Res; 2003 Dec 15; 9(17):6410-8. PubMed ID: 14695142
    [Abstract] [Full Text] [Related]

  • 11. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers.
    Zou B, Chim CS, Zeng H, Leung SY, Yang Y, Tu SP, Lin MC, Wang J, He H, Jiang SH, Sun YW, Yu LF, Yuen ST, Kung HF, Wong BC.
    Gastroenterology; 2006 Dec 15; 131(6):1835-43. PubMed ID: 17087954
    [Abstract] [Full Text] [Related]

  • 12. Methylation mediated silencing of TMS1/ASC gene in prostate cancer.
    Das PM, Ramachandran K, Vanwert J, Ferdinand L, Gopisetty G, Reis IM, Singal R.
    Mol Cancer; 2006 Jul 18; 5():28. PubMed ID: 16848908
    [Abstract] [Full Text] [Related]

  • 13. DNA methylation associated with polycomb repression in retinoic acid receptor β silencing.
    Moison C, Senamaud-Beaufort C, Fourrière L, Champion C, Ceccaldi A, Lacomme S, Daunay A, Tost J, Arimondo PB, Guieysse-Peugeot AL.
    FASEB J; 2013 Apr 18; 27(4):1468-78. PubMed ID: 23299856
    [Abstract] [Full Text] [Related]

  • 14. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
    Pulukuri SM, Rao JS.
    Oncogene; 2006 Aug 03; 25(33):4559-72. PubMed ID: 16786000
    [Abstract] [Full Text] [Related]

  • 15. Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas.
    Liu Y, Pang JC, Dong S, Mao B, Poon WS, Ng HK.
    Hum Pathol; 2005 Apr 03; 36(4):416-25. PubMed ID: 15892004
    [Abstract] [Full Text] [Related]

  • 16. Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer.
    Soejima H, Nakagawachi T, Zhao W, Higashimoto K, Urano T, Matsukura S, Kitajima Y, Takeuchi M, Nakayama M, Oshimura M, Miyazaki K, Joh K, Mukai T.
    Oncogene; 2004 May 27; 23(25):4380-8. PubMed ID: 15007390
    [Abstract] [Full Text] [Related]

  • 17. Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists.
    Mossman D, Kim KT, Scott RJ.
    BMC Cancer; 2010 Jul 12; 10():366. PubMed ID: 20618997
    [Abstract] [Full Text] [Related]

  • 18. CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations.
    Hesson LB, Wilson R, Morton D, Adams C, Walker M, Maher ER, Latif F.
    Oncogene; 2005 Jun 02; 24(24):3987-94. PubMed ID: 15806169
    [Abstract] [Full Text] [Related]

  • 19. Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs.
    Deng G, Kakar S, Okudiara K, Choi E, Sleisenger MH, Kim YS.
    Clin Cancer Res; 2009 Mar 01; 15(5):1519-26. PubMed ID: 19223499
    [Abstract] [Full Text] [Related]

  • 20. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
    Astuti D, Agathanggelou A, Honorio S, Dallol A, Martinsson T, Kogner P, Cummins C, Neumann HP, Voutilainen R, Dahia P, Eng C, Maher ER, Latif F.
    Oncogene; 2001 Nov 08; 20(51):7573-7. PubMed ID: 11709729
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.